Roche Holding AG (ROG) Price & Analysis

Compare

29 Followers

ROG Stock Chart & Stats

Day’s Range― - ―

52-Week RangeCHF231.90 - CHF313.80

Previous CloseN/A

Volume284.04K

Average Volume (3M)863.60K

Market Cap

$205.09B

Enterprise ValueCHF232.87B

Total Cash (Recent Filing)$17.32B

Total Debt (Recent Filing)$36.35B

Price to Earnings (P/E)21.6

Beta1.18

Next Earnings

Jan 29, 2026

EPS Estimate

9.27

Last Dividend Ex-Date

Mar 27, 2025

Dividend Yield3.79%

Share Statistics

EPS (TTM)11.08

Shares Outstanding702,562,700

10 Day Avg. Volume1,115,717

30 Day Avg. Volume863,598

Financial Highlights & Ratios

PEG Ratio-0.88

Price to Book (P/B)6.41

Price to Sales (P/S)3.26

P/FCF Ratio13.50

Enterprise Value/Market Cap1.14

Enterprise Value/Revenue3.79

Enterprise Value/Gross Profit5.12

Enterprise Value/Ebitda14.11

Forecast

1Y Price Target

$277.27

Price Target Upside8.31% Upside

Rating ConsensusHold

Number of Analyst Covering12

Bulls Say, Bears Say

Bulls Say

Pharma InvestmentRoche announced a $50 billion investment in the US for Pharma and diagnostics over the next five years, including research and development sites and new manufacturing facilities.

Pharma SalesQ2'25 sales beat consensus by 1%, driven by a stronger Pharmaceuticals (2% beat).

Product PerformancePhesgo was 19% above consensus accounting for 41% of the group sales beat on better demand in China and US.

Bears Say

CompetitionLonger-term growth appears challenged due to potential branded and biosimilar competition, which is likely to increase.

Market ChallengesA more challenging US market for Vabysmo drives FY25 sales growth closer to 18% YoY, compared to the pre-Q1 consensus of around 33% growth.

Regulatory SetbacksRecent safety and regulatory setbacks for key new launches contribute to downside risk for earnings expectations.

Roche Holding AG News

Adaptive Biotechnologies down 5% after Genentech pact terminated

Shares of Adaptive Biotechnologies (ADPT) are down 60c, or 5%, to $12.44 after the company disclosed in a...

2d ago

ADPT

CHRO

Natera says IMvigor011 bladder cancer trial achieves positive results

Natera (NTRA) announced positive topline results from the randomized, phase III IMvigor011 clinical trial in muscle-invasive bladder cancer....

2d ago

CHRO

NTRA

Trump Trade: Pharma tariff announcement likely ‘weeks away’

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by...

6d ago

AZN

BMY

Pharma tariff announcement likely ‘weeks away,’ Reuters reports

The announcement by President Donald Trump’s administration of the results of a probe into pharmaceutical imports and new...

7d ago

AZN

BMY

H.C. Wainwright doubles Insmed target to $240 on ‘pipeline-in-a-pill’ potential

H.C. Wainwright raised the firm’s price target on Insmed (INSM) to $240 from $120 and keeps a Buy...

7d ago

PFE

CHRO

Swiss leaders to discuss tariff situation with Roche, Novartis, Bloomberg says

Switzerland’s government, including Economy Minister Guy Parmelin and Interior Minister Elisabeth Baume-Schneider, have reached out with Roche (RHHBY)...

10d ago

NVS

CHRO

Trump, pharma industry discuss increasing medicine spending abroad, Reuters says

The Trump administration has been talking to drugmakers about ways to raise prices of medicines in Europe and...

12d ago

AZN

BMY

Roche downgraded to Underweight from Equal Weight at Morgan Stanley

Morgan Stanley downgraded Roche (RHHBY) to Underweight from Equal Weight with a price target of $39, down from...

12d ago

CHRO

Trump Weekly: President says raising tariffs on India ‘substantially’

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by...

15d ago

AEO

Trump says separate tariff announcements coming for semi chips, pharmaceuticals

President Donald Trump said while being interviewed on CNBC that separate tariff announcements are coming within the next...

15d ago

AMD

Roche Holding AG Faces Growth Challenges Amidst Competition and Regulatory Risks, Downgraded to Underweight

Morgan Stanley analyst Sarita Kapila downgraded the rating on Roche Holding AG to a Sell today, setting a...

12d ago

CHRO

Roche Reports Strong Sales Growth in H1 2025

Roche Holding ( ($RHHVF) ) has released its Q2 earnings. Here is a breakdown of the information Roche...

26d ago

Roche Holding AG: Hold Rating Amid Mixed Financial Signals and Strategic Challenges

Analyst Sarita Kapila of Morgan Stanley maintained a Hold rating on Roche Holding AG, retaining the price target...

27d ago

CHRO

Roche Holding AG: Mixed Q1’25 Results and Strategic U.S. Investments Justify Hold Rating

Morgan Stanley analyst Sarita Kapila has maintained their neutral stance on RHHVF stock, giving a Hold rating today....

4M ago

CHRO

ROG FAQ

What was Roche Holding AG’s price range in the past 12 months?

Roche Holding AG lowest stock price was CHF231.90 and its highest was CHF313.80 in the past 12 months.

What is Roche Holding AG’s market cap?

Roche Holding AG’s market cap is $205.09B.

When is Roche Holding AG’s upcoming earnings report date?

Roche Holding AG’s upcoming earnings report date is Jan 29, 2026 which is in 162 days.

How were Roche Holding AG’s earnings last quarter?

Roche Holding AG released its earnings results on Jul 24, 2025. The company reported CHF11.08 earnings per share for the quarter, beating the consensus estimate of CHF10.77 by CHF0.31.

Is Roche Holding AG overvalued?

According to Wall Street analysts Roche Holding AG’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Roche Holding AG pay dividends?

Roche Holding AG pays a Annually dividend of CHF9.7 which represents an annual dividend yield of 3.79%. See more information on Roche Holding AG dividends here

What is Roche Holding AG’s EPS estimate?

Roche Holding AG’s EPS estimate is 9.27.

How many shares outstanding does Roche Holding AG have?

Roche Holding AG has 702,562,700 shares outstanding.

What happened to Roche Holding AG’s price movement after its last earnings report?

Roche Holding AG reported an EPS of CHF11.08 in its last earnings report, beating expectations of CHF10.77. Following the earnings report the stock price went up 1.454%.

Which hedge fund is a major shareholder of Roche Holding AG?

Currently, no hedge funds are holding shares in CH:ROG

Company Description

Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. The company was founded in 1896 and is headquartered in Basel, Switzerland.

Roche Holding AG (ROG) Earnings & Revenues

Historic Earnings Reports

ROG Company Deck

ROG Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The call highlighted strong growth in pharmaceutical sales and robust pipeline development, particularly in oncology and neurology. However, challenges in the Diagnostics segment due to China's pricing reforms and mixed clinical trial results tempered the positive outlook. Additionally, regulatory setbacks and geopolitical uncertainties added caution.View all CH:ROG earnings summaries

ROG Stock 12 Month Forecast

Average Price Target

CHF277.27

▲(8.31% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"228":"CHF228","345":"CHF345","257.25":"CHF257.3","286.5":"CHF286.5","315.75":"CHF315.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":344.9999989287854,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF345.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":277.2717018163,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF277.27</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":229.9999992858569,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF230.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[228,257.25,286.5,315.75,345],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,257.1,263.86153837913736,270.6230767582747,277.384615137412,284.14615351654936,290.9076918956867,297.66923027482403,304.43076865396137,311.1923070330987,317.95384541223603,324.71538379137337,331.4769221705107,338.23846054964804,{"y":344.9999989287854,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,257.1,258.6516693704846,260.20333874096923,261.75500811145383,263.3066774819385,264.8583468524231,266.4100162229077,267.9616855933923,269.5133549638769,271.0650243343615,272.61669370484617,274.1683630753308,275.7200324458154,{"y":277.2717018163,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,257.1,255.01538456045054,252.9307691209011,250.8461536813516,248.76153824180213,246.67692280225268,244.5923073627032,242.50769192315371,240.42307648360423,238.33846104405478,236.2538456045053,234.16923016495582,232.08461472540637,{"y":229.9999992858569,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":276.65,"date":1722470400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":278.489,"date":1725148800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 18</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":256.516,"date":1727740800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":264.357,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 17</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":247.998,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":247.32,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 15</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":276.844,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 19</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":289.621,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 18</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":292.4,"date":1743465600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 18</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":269.3,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 14</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":264.7,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 15</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":260.7,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":257.1,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 14</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >